Search Results - "Cedervall, Ernst Peder"

Pirtobrutinib preclinical characterization: a highly selective, non-covalent (reversible) BTK inhibitor by Gomez, Eliana B, Ebata, Kevin, Randeria, Hetal S, Rosendahl, Mary S, Cedervall, Ernst Peder, Morales, Tony H, Hanson, Lauren M, Brown, Nicholas E, Gong, Xueqian, Stephens, Jennifer Rachelle, Wu, Wenjuan, Lippincott, Isabel, Ku, Karin S., Walgren, Richard A, Abada, Paolo B, Ballard, Joshua A, Allerston, Charles K, Brandhuber, Barbara J

“…Bruton tyrosine kinase (BTK), a nonreceptor tyrosine kinase, is a major therapeutic target for B-cell driven malignancies. However, approved covalent BTK…”
Get full text

Abstract P141: Preclinical characterization of LOX-24350, a highly potent and isoform-selective FGFR3 inhibitor by Ballard, Joshua A., Kercher, Timothy, Abraham, David, Brecht, Ryan, Brooks, Nathan A., Buckles, Thomas, Bume, Desta, Busha, David, Cedervall, Ernst Peder, Condroski, Kevin, Ebata, Kevin, Gharbi, Severine Isabelle, Hazlitt, Robert, Morales, Tony, Patel, Nisha, Podoll, Jessica, Urkalan, Kaveri, Villalain, Sandra Gomez, Walls, Shane, Watson, Faith, Yang, Peiyi, Brandhuber, Barbara J., Andrews, Steven W.

“…Alterations in the fibroblast growth factor receptors (FGFRs) have been identified as oncogenic drivers in many human cancers. Specifically, activating FGFR3…”
Get full text